LEADER 00769cam0 22002411 450 001 SOBE00025134 005 20120508104652.0 100 $a20120508d1983 |||||ita|0103 ba 101 $aeng 102 $aGB 200 1 $aDiscovering Shakespeare : a New Guide to the Plays$fJohn Russell Brown 210 $aLondon$cMacmillan$d1983 215 $aVIII, 168 p.$d22 cm 700 1$aBrown$b, John Russell$3AF00023609$4070$0131922 801 0$aIT$bUNISOB$c20120508$gRICA 850 $aUNISOB 852 $aUNISOB$j820$m38737 912 $aSOBE00025134 940 $aM 102 Monografia moderna SBN 941 $aM 957 $a820$b000743$gSI$d38737$1rovito$2UNISOB$3UNISOB$420120508104612.0$520120508104628.0$6rovito 996 $aDiscovering Shakespeare$9150182 997 $aUNISOB LEADER 05295nam 22006255 450 001 9910155329203321 005 20200703134114.0 024 7 $a10.1007/978-3-319-42400-2 035 $a(CKB)3710000000964759 035 $a(DE-He213)978-3-319-42400-2 035 $a(MiAaPQ)EBC4755492 035 $a(PPN)197457215 035 $a(EXLCZ)993710000000964759 100 $a20161201d2017 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAtrial Fibrillation and Percutaneous Coronary Intervention $eA Case-based Guide to Oral Anticoagulation, Antiplatelet Therapy and Stenting /$fedited by Andrea Rubboli, Gregory Y. H. Lip 205 $a1st ed. 2017. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2017. 215 $a1 online resource (VIII, 212 p. 52 illus., 30 illus. in color.) 311 $a3-319-42398-3 311 $a3-319-42400-9 320 $aIncludes bibliographical references at the end of each chapters. 327 $aAtrial fibrillation on vitamin K-antagonists undergoing elective coronary artery stenting for stable effort angina -- Atrial fibrillation on NOAC (dabigatran) undergoing elective coronary artery stenting for stable effort angina -- Atrial fibrillation on vitamin K-antagonist undergoing urgent coronary stenting for non ST-elevation acute coronary syndrome -- Atrial fibrillation on NOAC (rivaroxaban) undergoing urgent coronary stenting for non ST-elevation acute coronary syndrome -- Atrial fibrillation on vitamin K-antagonist undergoing emergency primary coronary stenting for ST-elevation acute myocardial infarction -- Atrial fibrillation on NOAC (apixaban) undergoing emergency primary coronary stenting for ST-elevation acute myocardial infarction -- Atrial fibrillation early complicating acute coronary syndrome treated with coronary artery stenting -- New-onset atrial fibrillation in a stable patient with remote coronary artery stenting -- Urgent surgery early after coronary stenting in a patient with atrial fibrillation on triple therapy of warfarin, aspirin and clopidogrel -- Urgent surgery early after coronary stenting in a patjent with atrial fibrillation on triple therapy of NOAC (a factor Xa-inhibitor), aspirin and clopidogrel -- Major bleeding early after coronary stenting in a patient with atrial fibrillation on triple therapy of warfarin, aspirin and clopidogrel -- Major bleeding early after coronary stenting in a patient with atrial fibrillation on triple therapy of NOAC (dabigatran), aspirin and clopidogrel. 330 $aThis book considers paradigmatic clinical cases in order to cast light on key issues relating to elective or emergency stent implantation and the use of oral anticoagulation (OAC) in patients with atrial fibrillation. The topics addressed include the optimal periprocedural antithrombotic treatment (uninterrupted vs interrupted OAC, intraprocedural use of heparin and glycoprotein IIb/IIIa inhibitors, etc.), the most appropriate type of stent (bare metal vs drug eluting vs ?bioactive?), the optimal regimen (e.g., triple therapy of OAC, aspirin, and clopidogrel vs the combination of OAC and a single antiplatelet agent), and the most suitable duration of the antithrombotic treatment prescribed at discharge (1 vs 6?12 months). The case-based management recommendations will be of wide practical value in the current health care context, where percutaneous coronary intervention is available even to patients with relevant co-morbidities, such as those warranting long-term OAC, and the indications for OAC are much broader than in the past. The book will appeal especially to clinical and interventional cardiologists, internal medicine specialists, hematologists, and family physicians and will also be of interest to cardiology and internal medicine residents and fellows. 606 $aCardiology 606 $aCardiac surgery 606 $aCritical care medicine 606 $aPharmacotherapy 606 $aAngiology 606 $aCardiology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33037 606 $aCardiac Surgery$3https://scigraph.springernature.com/ontologies/product-market-codes/H59028 606 $aIntensive / Critical Care Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/H3100X 606 $aPharmacotherapy$3https://scigraph.springernature.com/ontologies/product-market-codes/H69000 606 $aAngiology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33010 615 0$aCardiology. 615 0$aCardiac surgery. 615 0$aCritical care medicine. 615 0$aPharmacotherapy. 615 0$aAngiology. 615 14$aCardiology. 615 24$aCardiac Surgery. 615 24$aIntensive / Critical Care Medicine. 615 24$aPharmacotherapy. 615 24$aAngiology. 676 $a616.12 702 $aRubboli$b Andrea$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aLip$b Gregory Y. H$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910155329203321 996 $aAtrial Fibrillation and Percutaneous Coronary Intervention$91552908 997 $aUNINA